SURMOUNT-ADOLESCENTS: tirzepatide lowered BMI by 18.5% in adolescents at 72 weeks
In a phase 3 trial of 160 adolescents with obesity or overweight with obesity-related complications, weekly tirzepatide with lifestyle care lowered BMI by 18.5%, while BMI rose 0.5% with placebo.

At a glance
- Phase 3, double-blind trial: 160 adolescents aged 12 to younger than 18 years, randomised 2:1 to tirzepatide or placebo for 72 weeks, with lifestyle care.
- BMI fell by 18.5% with tirzepatide and rose by 0.5% with placebo; tirzepatide was superior (P < .001).
- All 10 key secondary outcomes favoured tirzepatide; gastrointestinal adverse events were most common, mostly mild to moderate.
Key result
Tirzepatide was superior to placebo: BMI fell 18.5% vs a 0.5% rise at week 72.
Change in BMI from baseline, Week 72
This report in under a minute
53 seconds. Free to use in your CME talks, with credit to Diabesity Rounds. Download the video · captions (SRT).
The study
SURMOUNT-ADOLESCENTS was a phase 3, randomised, double-blind, placebo-controlled trial published in JAMA. It ran at 31 medical research centres and hospitals in Canada, the Czech Republic, Israel, Italy, Poland and the US, from October 16, 2023, to June 2, 2026. It enrolled adolescents aged 12 years to younger than 18 years with obesity or overweight with at least 1 obesity-related complication.
A total of 160 participants were randomised 2:1 to once-weekly subcutaneous tirzepatide (n = 109) or placebo (n = 51) for 72 weeks. Tirzepatide was escalated to the maximum tolerated dose (5, 10 or 15 mg). Both groups also received a healthy lifestyle intervention. At baseline, mean age was 14.6 years, 61.9% were female, mean body weight was 109.7 kg and mean BMI was 38.6. The primary end point was percent change in BMI from baseline to week 72.
What they found
At week 72, BMI fell by 18.5% with tirzepatide and rose by 0.5% with placebo. The estimated treatment difference was -19.0 percentage points (95% CI, -23.9 to -14.1; P < .001). The authors report that tirzepatide was superior to placebo.
All 10 key secondary outcomes showed statistically significant differences favouring tirzepatide. These included BMI reductions of at least 5%, 10%, 15% and 20%, BMI SD score, BMI as a percentage of the 95th percentile, body weight, waist circumference and physical functioning. A BMI reduction of at least 5% was reached by 79.6% of the tirzepatide group and 28.5% of the placebo group (risk difference 51.2 percentage points; 95% CI, 36.3 to 66.1; P < .001). The abstract does not give the size of each of the other secondary results.
The most common adverse events with tirzepatide were gastrointestinal, mostly mild to moderate. The abstract does not report the rates of serious adverse events or of stopping treatment due to adverse events.
How much weight to give it
This is a randomised, double-blind, phase 3 trial with a placebo group and a 72-week treatment period, which is a strong design for this question. The main result was large and the confidence interval was well away from zero.
There are limits. The trial was modest in size, with 160 participants. It was run in North America, Europe and Israel, so its results may not carry over directly to Indian adolescents. The main outcomes are BMI and body measures, not long-term health events, and the abstract does not report what happens after treatment stops. The abstract does not report funding. Detailed safety data, growth and puberty outcomes are not given in the abstract.
For your clinic
For adolescents with obesity, this trial adds randomised evidence that tirzepatide, used with a healthy lifestyle programme, lowered BMI more than placebo over 72 weeks. The most common adverse events with tirzepatide were gastrointestinal, mostly mild to moderate. Lifestyle care stayed part of treatment in both groups.
Read the full paper before using these results with a young patient, especially the safety tables and the dose escalation details.
Source
Tirzepatide in Adolescents With Obesity: The SURMOUNT-ADOLESCENTS Randomized Clinical Trial.
Kelly AS, Pamidipati KC, Rachmiel M et al.. JAMA. 15 November 2026
Teaching a session? Download this report as a slide (PNG, free to use with credit).
For registered medical practitioners. This report summarises published research and is not advice for individual patients. Read the full paper and current guidelines before changing practice. Found an error? Write to editor@diabesityrounds.com; see our corrections and editorial policy.
More on glp-1 and incretin drugs
- Phase 3 trial reports BMI changes with liraglutide 3.0 mg in children aged 6 to 11Trial registry · 17 November 2026
- Weekly semaglutide lowered BMI in children aged 6 to under 12 with obesity: phase 3 trialRandomised trial · 17 November 2026
- Weekly ribupatide lowers body weight over 48 weeks in Chinese adults without diabetesRandomised trial · 17 November 2026
- CagriSema 1.7 mg and 1.0 mg each cut bodyweight more than placebo in REDEFINE 9Randomised trial · 16 November 2026
Go deeper
- CASPIAN Certificate in Obesity MedicineRegister interest for the next batch
- Beta Cell AcademyCME for doctors in Hyderabad
Today's Rounds, in your inbox at 8am
The day's reports each morning, and Weekend Rounds on Saturday. Free, no advertising.
Or follow on WhatsApp or Telegram (every report, as it is published), watch on YouTube, listen on Spotify or Apple Podcasts, or follow on LinkedIn. Not sure? Pick one.